Sign In
Buy LMLLF
$0.0037
+0 (+0%)
At Close: Jun 22, 2026
PharmaDrug Inc announced a positive research result for its preclinical cancer study which evaluated the effectiveness of cepharanthine-2HCI alone or when used in combination with standard of care (So
PharmaDrug commissions TIBI for advancing psychedelics program with analogue DMT formulation to cure eye diseases
09:54am, Friday, 05'th Nov 2021
PharmaDrug Inc announced that the Terasaki Institute for Biomedical Innovation (TIBI) will commence in vitro characterization studies on PharmaDrug's short-list of N, N-dimethyltryptamine (DMT) analog
PharmaDrug boosts its product portfolio ahead of anticipated legalization of cannabis in Germany
07:54pm, Monday, 01'st Nov 2021
PharmaDrug Inc said its German distribution subsidiary, Pharmadrug Production GmbH, has boosted its product portfolio ahead of the anticipated legalization of cannabis for adult use in Germany. The C
PharmaDrug says its stock is now trading on OTCQB Venture Market in the US
09:24am, Wednesday, 20'th Oct 2021
PharmaDrug Inc said its common shares began trading on the OTCQB Venture Market (OTCQB) in the US on October 19, 2021, under the symbol ‘LMLLF'. The company noted its shares will continue to trade o
PharmaDrug hails pre-clinical results on Cepharanthin to treat cancer; eying FDA IND-enabling animal studies in 4Q
09:16am, Friday, 15'th Oct 2021
PharmaDrug Inc has welcomed interim pre-clinical results for its cepharanthine drug, which have validated its ambition to carry out Food and Drug Administration (FDA) investigational new drug (IND)-e
Cepharanthine reproducibly demonstrates potential as a monotherapy in treating multiple cancers with unsatisfactory treatment optionsIdentified 4 cancer types where cepharanthine provides additive or
PharmaDrug gets pre-IND meeting request granted by US FDA for oral antiviral drug Cepharanthine to potentially treat coronavirus
12:21pm, Tuesday, 28'th Sep 2021
PharmaDrug Inc. revealed that it has been granted a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for the clinical development of its patented enteric-c
PharmaDrug gets pre-IND meeting request granted by FDA for oral antiviral drug Cepharanthine to potentially treat coronavirus
12:15pm, Tuesday, 28'th Sep 2021
PharmaDrug Inc. revealed that it has been granted a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for the clinical development of its patented enteric-c
Toronto, Ontario--(Newsfile Corp. - September 28, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development a
PharmaDrug's Super Smart launches Slim MycoWeRx brand of functional mushrooms
09:48am, Thursday, 23'rd Sep 2021
PharmaDrug Inc. has announced that its Super Smart division is launching its own premium blend of functional mushrooms.
PharmaDrug's Super Smart Launches Slim MycoWeRx Brand of Functional Mushrooms
08:00am, Thursday, 23'rd Sep 2021
Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, deve
PharmaDrug says experienced pharma analyst and executive David Kideckel is joining its board
10:01am, Monday, 30'th Aug 2021
PharmaDrug Inc. has announced that experienced pharma analyst and executive David Kideckel will be joining its board effective immediately.
Biotech Veteran David Kideckel Joins the Board of PharmaDrug
08:00am, Monday, 30'th Aug 2021
Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, develo
PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT
08:57am, Thursday, 26'th Aug 2021
On Wednesday, PharmaDrug Inc. (CSE:PHRX) (OTC:LMLLF), a company researching DMT and other psychedelics for medical purposes, announced a new clinical trial agreement with Johns Hopkins University, one
PharmaDrug announces clinical research collaboration with Johns Hopkins University to evaluate DMT in a comparative clinical study
08:58am, Wednesday, 25'th Aug 2021
PharmaDrug Inc announced it has entered into a clinical trial agreement with the Johns Hopkins University (JHU) to conduct a clinical study comparing acute and enduring psychological and neural effect
